Acid-suppressing drugs and gastroesophagael reflux disease as risk factors for acute pancreatitis - Results from a Swedish case-control study

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 3, 2006, Pages 141-149

  Sundström, Anders ^a,b   Blomgren, Kerstin ^b   Alfredsson, Lars ^c   Wiholm, Bengt Erik ^b  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

^b University Hospital   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acute pancreatitis; Adverse drug reaction; Case control study; Gastritis; Gastroesophageal reflux disease; h2 antagonists; Inflammatory bowel disease; Pharmacoepidemiology; Proton pump inhibitors

Indexed keywords

ANTACID AGENT; ANTIINFLAMMATORY AGENT; CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; LANSOPRAZOLE; MESALAZINE; OLSALAZINE; OMEPRAZOLE; PREDNISOLONE; PROTON PUMP INHIBITOR; RANITIDINE; SALAZOSULFAPYRIDINE;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EXPOSURE; ENTERITIS; FEMALE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HOSPITALIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; POPULATION RESEARCH; PRIORITY JOURNAL; REGISTER; RISK FACTOR; SWEDEN; TELEPHONE;

ADULT; AGED; AGED, 80 AND OVER; ANTACIDS; CASE-CONTROL STUDIES; ENZYME INHIBITORS; FEMALE; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERVIEWS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PANCREATITIS; PHARMACOEPIDEMIOLOGY; PROTON PUMPS; REGISTRIES; RISK FACTORS; SWEDEN;

EID: 33645286204     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1137     Document Type: Article

References (27)

1. Johnston DH, Cornish AL. Acute pancreatitis in patients receiving chlorothiazide. JAMA 1959; 170: 2054-2056.
2. Bergholm U, Langman M, Rawlins M, et al. Drug induced acute pancreatitis. Pharmacoepidemiol Drug Safe 1995; 4: 329-334.
3. Sturdevant RA, Singleton JW, Deren JL, et al. Azathioprine-related pancreatitis with Crohn's disease. Gastroenterology 1979; 77: 883-886
4. Faulds D, Brodgren RN. Didanosine: a review of its antiviral activity, pharmacokinetc and therapeutic potential in human immunodeficiency virus infections. Drugs 1992; 44: 94-116.
5. Evans JMM, McMahon AD, Steinke D, et al. Do H2-receptor antagonists cause acute pancreatitis? Pharmacoepidemiol Drug Safe 1998; 7: 383-388.
6. Eland IA, Alvarez H, Stricker BH, et al. The risk of acute pancreatitis associated with acid-suppressing drugs. Br J Clin Pharmacol 2000; 49: 473-478.
7. Lancashire RJ, Cheng K, Langman MJ. Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. Aliment Pharmacol Ther 2003; 17: 887-893.
8. Blomgren KB, Sundstrom A, Steineck G, et al. A Swedish Case Control Network for studies of drug induced morbidity - acute pancreatitis. Eur J Clin Pharmacol 2002; 58: 275-283.
9. Rasmussen H, Fonager K, Sorensen H, et al. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1999; 2: 199-201.
10. Matsumoto T, Matsui T, Iida M, et al. Acute pancreatitis as a complication of Crohn's disease. Am J Gastroenterol 1989; 84: 804-807.
11. Nogueira JR, Feedman MA. Acute pancreatitis as a complication of Imuran therapy in regional enteritis. Gastroenterology 1972; 62: 1040-1041.
12. Adachi E, Okazakik K, Matsushima Y, et al. Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis. J Pancreatol 1999; 5: 217-221.
13. Haber CJ, Meltzer SJ, Present DH, et al. Nature and course of pancreatitis caused by 6-mercaptupurine in the treatment of inflammatory bowel disease. Gastroenterology 1986; 91: 982-986.
14. Blomgren KB, Sundstrom A, Steineck G, et al. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diab Care 2002; 25: 298-302.
15. World Health Organization. Anatomical therapeutical classification (ATC) index including defined daily dosage (DDD) for plain substances. Oslo, Norway.
16. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol 1974; 99: 325-332.
17. Stata for Windows, version 8. Stata Corporation, College Station, Texas, USA.
18. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. NEJM 1999; 340: 825-831.
19. Wilkinson ML, O'Driscoll R, Kiernan TJ. Cimetidine and pancreatitis. Lancet 1981; 1: 610-611.
20. Herrmann R, Shaw RG, Fone DJ. Ranitidine-associated recurrent acute pancreatitis. Aust NZ Med 1990; 20: 243-244.
21. Garcia Rodriguez LA, Wallander M-A, Snicker B. The risk of acute liver injury associated with Cimetidine and other acid-suppressing anti-ulcer drugs. Br J Clin Pharmacol 1997; 43: 183-188.
22. Keisu M, Ekman E. Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Eur J Clin Pharmacol 1992; 43: 215-218.
23. Lewis SC, Langman MJS, Laporte JR, et al. Dose response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: A meta-analysis based on individual patient data. Br J Clin Pharmacol 2002; 54: 320-326.
24. Roujeau J-C, Kelly J, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. NEJM 1995; 333: 1600-1607.
25. Apoteket AB. Svensk Läkemedelsstatistik, 1995; 1998. Stockholm (Sweden).
26. Appelroos S, Borgström A. Incidence, aetiology and mortality rate of acute pancreatitis over 10 years in a defined urban population in Sweden. Br J Surg 1999; 86: 465-470.
27. Steinberg WM. Acute drug and toxin induced pancreatitis. Hosp Pract (Off Ed) 1995; 20: 95-102.